FDA Backs Rotarix After Advisory Panel’s Support

The FDA is advising resumed use of GlaxoSmithKline’s Rotavirus vaccine Rotarix and the continued use of Merck’s vaccine Rotateq after an advisory panel voiced support for the contaminated vaccines. The Vaccines and Related Biological Products Advisory Committee told the FDA that the vaccines’ benefits appear to outweigh the risks, but it recommended evaluating the long-term effects now that DNA fragments from porcine circovirus-1 (PCV-1) have been found in both vaccines and fragments from PCV-2 were found in Rotateq.
Drug Industry Daily